AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05935254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaque removal efficacy of children's soft manual toothbrush (Oral-B Stages 6-12 years; Procter & Gamble, Cincinnati, OH, United States)
Description: At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with a manual toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
Study NCT05935254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plaque removal efficacy of children's soft manual toothbrush (Oral-B Stages 6-12 years; Procter & Gamble, Cincinnati, OH, United States)
Description: At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with a manual toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
Study NCT06358222 — intervention group
Intervention type: PROCEDURE
Intervention: Blood ctDNA + methylation + PET-CT and Postoperative pathology
Description: A highly sensitive tumor-naïve MRD panel of ctDNA will be employed to detect preoperative blood. Some patients will undergo methylation profiling to prospectively establish LNMs-specific ctDNA methylation signatures.
Study NCT06358222 — intervention group
Intervention type: PROCEDURE
Intervention: MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA
Description: A certain number (depending on the Results of Stage 1) of patients requiring invasive mediastinoscopy or EBUS-TBNA, based on the clinical guidelines, will be included for blood ctDNA mutation/methylation profile (or combined PET-CT), and the detection rate of LNMs will be assessed in patients with negative preoperative blood ctDNA mutation/methylation (or combined PET-CT). The accuracy of predicting LNMs will be compared with that of patients with negative or positive preoperative blood ctDNA mutation/methylation (or combined PET-CT).
Study NCT06358222 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative lymph node dissection
Description: For patients with negative preoperative blood negative testing (ctDNA mutation/methylation profiles alone or in combination with PET-CT), systematic lymph node sampling/dissection and no lymph node dissection will be grouped and compared. Regular follow-up is performed to investigate the impact on long-term MRD negative duration and prognosis.
Study NCT06088420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .
Description: Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .
Study NCT06705140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose (LD) RSVt vaccine
Description: Pharmaceutical form:~Liquid for nasal spray~Route of administration: Intranasal
Study NCT06705140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose (SD) RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
Study NCT06705140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose (HD) RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
Study NCT06705140 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
Study NCT06712901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Median Ranked Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
Study NCT06712901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overall Preferred Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
Study NCT06712901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black American Preferred Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
Study NCT06712901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White American Preferred Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.
Study NCT06712901 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: There will be no message content of cancer screening and sharing intentions in this arm.
Study NCT06711926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distilled water
Description: Participants will receive 600ml distilled water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
Study NCT06711926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-skimmed milk
Description: Participants will receive \~600ml semi-skimmed milk with a strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
Study NCT06711926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey permeate
Description: Participants will receive \~600ml whey permeate (30g sachet, rehydrated with distilled water)with strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
Study NCT06719141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
Study NCT06719141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
Study NCT04846361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal hygiene wash
Description: vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
Study NCT04846361 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo wash
Description: placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
Study NCT05252793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education based on the health belief model
Description: After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
Study NCT04788095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in an app-based mindfulness program
Study NCT04788095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04788095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06761703 — intervention group
Intervention type: DEVICE
Intervention: TAP® Micro Select Device (Touch Activated Phlebotomy)
Description: The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.
Study NCT06763835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood is drawn to test for specific biomarkers
Description: After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.
Study NCT06767137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is a gold-standard, evidence-based treatment combining techniques to improve the clinical symptomatology of insomnia. Delivered in six 90-minute group sessions over six weeks, it includes: sleep education (i.e. understanding sleep mechanisms and influencing factors), bedtime restriction (i.e. aligning bedtimes with reported sleep duration), stimulus control (i.e. getting out of bed when unable to sleep), cognitive therapy (i.e. addressing dysfunctional sleep beliefs), relaxation techniques (i.e. using methods like progressive muscle relaxation).
Study NCT06767137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime restriction (BRT)
Description: Bedtime Restriction Therapy (BRT): A behavioral intervention aimed at improving the clinical symptomatology of insomnia by aligning time spent in bed with reported sleep duration. Participants attend four 60-minute group therapy sessions over six weeks. The intervention includes: setting individualized sleep windows based on sleep diaries, regular adjustment of sleep schedules to enhance sleep pressure, group discussions to address implementation challenges and maintain motivation.~BRT focuses exclusively on bed time restriction without additional cognitive or relaxation components, making it a simplified, resource-efficient approach to treating insomnia.
Study NCT06764940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
Study NCT06764940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone in combination with capecitabine
Description: UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study NCT06764940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone in combination with capecitabine
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study NCT06764940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone in combination with capecitabine
Description: Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study NCT06766318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group A will receive cryo-ultrasound therapy combined with conventional physical therapy for two months
Description: Cryo-ultrasound therapy combines two therapeutic methods: cryotherapy (using cold) and ultrasound (using sound waves). The ultrasound component provides a therapeutic heating effect, improving blood circulation and tissue flexibility, while the cold component reduces pain and inflammation
Study NCT06766318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER therapy
Description: group B will receive LASER therapy combined with conventional physical therapy.
Study NCT06766383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPT-simulated patients
Description: GPT-simulated patients
Study NCT06766383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional role-playing
Description: traditional role-playing
Study NCT06775041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.
Study NCT06775041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
Study NCT06775041 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lonafarnib
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
Study NCT06775041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
Study NCT06770790 — intervention group
Intervention type: OTHER
Intervention: strain echocardiography
Description: HR, MAP, SBP, and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Two transthoracic 2D echocardiographic examinations will be performed immediately before and 15 minutes after TEA. The examinations include apical four-, two-, and three-chamber projections, mitral and aortic Doppler flow velocities. Standard measurements of left ventricular systolic function include left ventricular volumes (indexed to body surface area, BSA), left ventricular ejection fraction (LVEF) according to the modified Simpson rule, time and velocity integral in the left ventricular outflow tract (TVI-LVOT), and stroke volume (SV) (= π x LVOT radius2 x TVI-LVOT). Stroke volume index (SVI) will be calculated as SV/BSA. Mitral and aortic Doppler flow profiles, left ventricular isovolumetric relaxation time, maximum flow velocity will be recorded for m
Study NCT06773078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intake group
Description: Intake of a breakfast containing the foods of interest avocado (80gr), corn tortilla (60 gr), nopal (200 gr), guava (108 gr), mango (100 gr), amaranth (14 gr).
Study NCT06773078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Average intake group
Description: Intake of a breakfast containing the foods of interest avocado (40gr), corn tortilla (30 gr), nopal (100 gr), guava (54 gr), mango (50 gr), amaranth (7 gr).
Study NCT06770088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vnacicizumab
Description: Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.
Study NCT06772129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Studies have been reviewed and no lavender aromatherapy has been found to be used for delirium.
Study NCT06770504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YTS109
Description: In this study, subjects will receive YTS109 Cell Injection(0.5-1E6 STAR+T cell/kg) once.
Study NCT06770868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific reconstruction plate for patients suffering from mandibular segmental defects
Description: Patients with mandibular segmental defect including coronoidectomy managed with patient specific reconstruction plate with custom made temporalis tendon enthesis
Study NCT06771895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise and nutritional intervention
Description: The intervention consists of a combined exercise and nutritional intervention. All subjects will perform 20 weeks of supervised resistance and endurance type exercise training 2 to 3 days per week. Leg press, leg extension, calf raises, chest press, shoulder press, horizontal row and vertical lateral pull exercise will be performed on weightlifting machines in addition to cycling on an ergometer. The dietary intervention aims to attain a diet that comprises sufficient protein, with a minimum of 1.2 g/kg bodyweight/day distributed as 25-30 g protein per main meal, and is otherwise in line with the Dutch Healthy Diet guidelines. In support, subjects will consume a daily multi-nutrient supplement containing leucine-enriched whey protein, vitamin D, omega-3 long chain polyunsaturated fatty acids (n-3 lcPUFA), calcium, choline and pre- and probiotics, which will be ingested pre-sleep. There will be an additional supplement intake moment following each training session.
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: Pain-Pressure Threshold Measurement With an Algometer
Description: The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral thigh, pretibial region and left forearm as remote site and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~Bilateral thigh: Mid-thigh anterior surface Bilateral pretibial region: Anterior proximal 1/3 of the pretibial area Bilateral forearm volar side center as control point
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: Central Sensitization Inventory
Description: The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization.
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: Numeric Rating Scale
Description: Leg pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: Lower Extremity Functional Scale
Description: The lower extremity functional scale is a valid patient-rated outcome measure for the measurement of lower extremity function. The scale consist of 4 groups with 20 questions. The questions in these group focus on activities with increasing physical demands like questions from walking between rooms to running on uneven ground. The scoring of this scale varies from 0 (extreme difficulty/unable to perform activity) to 4 (no difficulty). The total score can be obtained by summing the scores of the individual items. The maximum score of 80 indicates no functional limitations and the minimum score of 0 indicates extreme limitations.
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: Short form 12
Description: The Short form 12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.The scoring yields two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).Utilize the norm-based scoring system to interpret PCS and MCS scores, with a mean of 50 and a standard deviation of 10 in the general population.Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: lower extremity volumetric measurement
Description: It is calculated by converting the circumference measurements taken at 4 cm intervals from the ankle to the proximal thigh into lower extremity volume with Excel.
Study NCT06770634 — intervention group
Intervention type: OTHER
Intervention: lower extremity circumference measurement
Description: bilateral tuberosity tibia, 20 cm proximal tuberosity tibia, tuberosity tibia 10 cm distal and ankle level